143 related articles for article (PubMed ID: 34628794)
21. OLIG2 as a specific marker of oligodendroglial tumour cells.
Marie Y; Sanson M; Mokhtari K; Leuraud P; Kujas M; Delattre JY; Poirier J; Zalc B; Hoang-Xuan K
Lancet; 2001 Jul; 358(9278):298-300. PubMed ID: 11498220
[TBL] [Abstract][Full Text] [Related]
22. Ultrastructural characterization of oligodendroglial-like cells in central nervous system tumors.
Cenacchi G; Giangaspero F; Cerasoli S; Manetto V; Martinelli GN
Ultrastruct Pathol; 1996; 20(6):537-47. PubMed ID: 8940761
[TBL] [Abstract][Full Text] [Related]
23. Challenging diagnosis: oligodendroglioma versus extraventricular neurocytoma.
Mut M; Güler-Tezel G; Lopes MB; Bilginer B; Ziyal I; Ozcan OE
Clin Neuropathol; 2005; 24(5):225-9. PubMed ID: 16167546
[TBL] [Abstract][Full Text] [Related]
24. Nogo-a expression in glial CNS tumors: a tool to differentiate between oligodendrogliomas and other gliomas?
Kuhlmann T; Gutenberg A; Schulten HJ; Paulus W; Rohde V; Bruck W
Am J Surg Pathol; 2008 Oct; 32(10):1444-53. PubMed ID: 18685489
[TBL] [Abstract][Full Text] [Related]
25. So-called malignant and extra-ventricular neurocytomas: reality or wrong diagnosis? A critical review about two overdiagnosed cases.
Vallat-Decouvelaere AV; Gauchez P; Varlet P; Delisle MB; Popovic M; Boissonnet H; Gigaud M; Mikol J; Hassoun J
J Neurooncol; 2000 Jun; 48(2):161-72. PubMed ID: 11083081
[TBL] [Abstract][Full Text] [Related]
26. Histological spectrum of ependymomas and correlation of p53 and Ki-67 expression with ependymoma grade and subtype.
Suri VS; Tatke M; Singh D; Sharma A
Indian J Cancer; 2004; 41(2):66-71. PubMed ID: 15318011
[TBL] [Abstract][Full Text] [Related]
27. Predominant expression of OLIG2 over ID2 in oligodendroglial tumors.
Mikami S; Hirose Y; Yoshida K; Kawase T; Ohnishi A; Nagashima K; Mukai M; Okada Y; Ikeda E
Virchows Arch; 2007 May; 450(5):575-84. PubMed ID: 17431671
[TBL] [Abstract][Full Text] [Related]
28. [Application of new immunohistochemical markers in diagnosis of central nervous system tumors].
Teng LH; Lu DH
Zhonghua Bing Li Xue Za Zhi; 2009 Mar; 38(3):207-10. PubMed ID: 19575865
[No Abstract] [Full Text] [Related]
29. Podoplanin is a potential marker for the diagnosis of ependymoma: a comparative study with epithelial membrane antigen (EMA).
Ishizawa K; Komori T; Shimada S; Hirose T
Clin Neuropathol; 2009; 28(5):373-8. PubMed ID: 19788053
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic implications of IDH1-R132H and OLIG2 expression patterns in rare and challenging glioblastoma variants.
Joseph NM; Phillips J; Dahiya S; M Felicella M; Tihan T; Brat DJ; Perry A
Mod Pathol; 2013 Mar; 26(3):315-26. PubMed ID: 23041832
[TBL] [Abstract][Full Text] [Related]
31. [Central neurocytoma--the need for reassessment of histological diagnoses in tumors in the lateral and third ventricles].
Gabrovski S; Kamenova M
Khirurgiia (Sofiia); 1997; 50(5):14-9. PubMed ID: 9739866
[TBL] [Abstract][Full Text] [Related]
32. Clinicopathological analysis of central and extraventricular neurocytoma: a report of 17 cases.
Zhu P; Yan F; Ma Y; Ao Q
J Huazhong Univ Sci Technolog Med Sci; 2010 Dec; 30(6):746-50. PubMed ID: 21181365
[TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical comparison of chordoma with chondrosarcoma, myxopapillary ependymoma, and chordoid meningioma.
Cho HY; Lee M; Takei H; Dancer J; Ro JY; Zhai QJ
Appl Immunohistochem Mol Morphol; 2009 Mar; 17(2):131-8. PubMed ID: 19521276
[TBL] [Abstract][Full Text] [Related]
34. Clear cell ependymoma: a mimic of oligodendroglioma: clinicopathologic and ultrastructural considerations.
Min KW; Scheithauer BW
Am J Surg Pathol; 1997 Jul; 21(7):820-6. PubMed ID: 9236838
[TBL] [Abstract][Full Text] [Related]
35. Oligodendrogliomas with neurocytic differentiation. A report of 4 cases with diagnostic and histogenetic implications.
Perry A; Scheithauer BW; Macaulay RJ; Raffel C; Roth KA; Kros JM
J Neuropathol Exp Neurol; 2002 Nov; 61(11):947-55. PubMed ID: 12430711
[TBL] [Abstract][Full Text] [Related]
36. A case of oligodendroglioma with prominent neuronal differentiation.
Hirose T; Nobusawa S; Nakazato Y; Sasaki A
Hum Pathol; 2013 Oct; 44(10):2353-9. PubMed ID: 24054724
[TBL] [Abstract][Full Text] [Related]
37. Strong OLIG2 expression in supratentorial ependymoma, ZFTA fusion-positive: A potential diagnostic pitfall.
de Castro JVA; Kulikowski LD; Wolff BM; Natalino R; Carraro DM; Torrezan GT; Scapulatempo Neto C; Amancio CT; Canedo FSNA; Feher O; Costa FD
Neuropathology; 2024 Apr; 44(2):167-172. PubMed ID: 37855183
[TBL] [Abstract][Full Text] [Related]
38. Clinical significance of ABCA2' a possible molecular marker for oligodendrogliomas.
Soichi O; Masanori N; Hideo T; Kazunori A; Nobuya I; Jun-ichi K
Neurosurgery; 2007 Apr; 60(4):707-14; discussion 714. PubMed ID: 17415208
[TBL] [Abstract][Full Text] [Related]
39. Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: use of YKL-40, ApoE, ASCL1, and NKX2-2.
Rousseau A; Nutt CL; Betensky RA; Iafrate AJ; Han M; Ligon KL; Rowitch DH; Louis DN
J Neuropathol Exp Neurol; 2006 Dec; 65(12):1149-56. PubMed ID: 17146289
[TBL] [Abstract][Full Text] [Related]
40. Oligodendroglioma: pathology and molecular biology.
Engelhard HH; Stelea A; Cochran EJ
Surg Neurol; 2002 Aug; 58(2):111-7; discussion 117. PubMed ID: 12453646
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
